A groundbreaking partnership has emerged between CN Bio, a prominent provider of Organ-on-a-chip (OOC) systems, and Pharmaron, a leading R&D service platform for the life sciences industry. This collaboration aims to validate and integrate OOC technologies into Pharmaron's R&D processes while exploring new applications to meet unmet needs in drug discovery. Initially focusing on validating CN Bio’s PhysioMimix technology for disease modeling, toxicity testing, and ADME studies, the partnership will expand to co-develop innovative solutions tailored to evolving challenges in global drug research.
The collaboration underscores the importance of leveraging cutting-edge OOC technologies to address current market gaps, such as testing immune-mediated organ damage. It aligns with the FDA's initiative to phase out animal testing requirements for monoclonal antibodies and other drugs, promoting more ethical advancements that reduce costs and improve human health. Both companies aim to enhance preclinical understanding through translational science and accelerate drug development by sharing resources and expertise.
Pioneering Validation and Integration of Advanced Technologies
This strategic alliance centers on validating CN Bio’s PhysioMimix technology for existing applications in disease modeling, toxicity testing, and ADME studies. Upon successful validation, the two organizations will jointly adopt the platform in key R&D areas and co-develop novel applications to broaden the capabilities of OOC technologies. The integration of these advanced tools at Pharmaron’s global facilities signifies a significant step toward addressing critical challenges in drug discovery.
By installing PhysioMimix instruments at Pharmaron’s sites worldwide, CN Bio ensures access to state-of-the-art OOC solutions tailored to emerging R&D demands. This collaborative effort not only validates the effectiveness of CN Bio’s technology but also fosters innovation through shared resources and expertise. The initial phase focuses on ensuring the reliability and applicability of the technology across various domains, setting a solid foundation for future developments. As the validation process progresses, both entities aim to refine and optimize the use of OOC systems, enhancing their ability to model diseases accurately and conduct comprehensive toxicity assessments.
Driving Ethical Innovation in Drug Discovery
In light of the FDA's recent announcement regarding the reduction of animal testing for monoclonal antibodies and other pharmaceuticals, this partnership holds particular significance. The collaboration seeks to expedite advancements in human-relevant models, addressing critical gaps in the market, such as immune-mediated organ damage testing. By combining forces, CN Bio and Pharmaron aim to contribute to global momentum towards more ethical and cost-effective drug development practices.
Dr. Tomasz Kostrzewski from CN Bio emphasizes the importance of aligning technological innovations with regulatory trends to foster meaningful progress. The partnership leverages Pharmaron's commitment to continuous innovation, aiming to elevate the quality of services provided to partners in drug discovery and development. Through integrating OOC technology, Pharmaron enhances its translational science capabilities, improving the understanding of drug behavior at the preclinical stage. This synergy exemplifies how collaboration can drive transformative changes, reducing reliance on traditional methods while advancing human health more effectively. Ultimately, the partnership positions both companies as leaders in promoting ethical advancements and fostering a more sustainable future in drug research and development.